XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.1

License, Clinical Trial and Sponsored Research Agreements (Tables)

12 Months Ended

Dec. 31, 2018

License Agreement Disclosure [Abstract]

Research and Development Arrangement, Contract to Perform for Others [Table Text Block]

For the years ended December 31, 2018 and 2017, the Company recorded the following expense in research and development for licenses acquired:

		For the year ended December 31,
($ in thousands)		2018				2017
City of Hope
Manufacturing		$	75			$	-
IL13Rα2			-				500
IV/ICV			-				125
PSCA			-				300
HER2			200				600
CS1			-				600
Harvard University - CRISPR			-				250
UCLA			-				200
Fred Hutch - CD20			-				300
St. Jude - XSCID			1,000				-
Fortress PIK Dividend			2,085				9,558
Total		$	3,360			$	12,433

For the years ended December 31, 2018 and, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

		For the year ended December 31,
		2018				2017
($ in thousands)
City of Hope		$	2,000			$	2,000
City of Hope - CD123			835				1,227
City of Hope - IL13Rα2			1,056				1,578
City of Hope - Manufacturing			458				-
Fred Hutch - CD20			1,301				614
BIDMC - CRISPR			69				138
Total		$	5,719			$	5,557

X

- References

No definition available.

+ Details

Name:	mbio_LicenseAgreementDisclosureAbstract
Namespace Prefix:	mbio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration